Combining BET inhibition with SMAC mimetics restricts tumor growth and triggers immune surveillance in preclinical cancer models

Summary: Second mitochondrial activator of caspase (SMAC) mimetics (SMACm) and bromodomain and extra-terminal domain (BET) inhibitors (BETi) are two distinct classes of novel anticancer therapeutics. So far, broad clinical benefit for either monotherapy has not been achieved, calling for effective c...

Disgrifiad llawn

Manylion Llyfryddiaeth

Prif Awduron:	Ksenija Slavic Obradovic, Florian Ebner, Artem V. Artemov, Martina Miotto, Paula-Elena Traexler, Robin Jacob, Ha Pham Thi Thanh, Regina Ruzicka, Andreas Wernitznig, Ines Baumann, Daniel Gerlach, Maria-Antonietta Impagnatiello, Salvatore Siena, Mary Murphy, Reniqua House, Ulrich Reiser, Valeria Santoro, Johannes Popow, Sebastian Carotta, Anke Baum, Jesse Lipp, Alberto Bardelli, Ulrike Tontsch-Grunt, Mariangela Russo, Martin Aichinger
Fformat:	Artigo
Iaith:	Inglês
Cyhoeddwyd:	Elsevier 2025-09-01
Cyfres:	Cell Reports Medicine
Pynciau:	SMAC mimetic cIAP BET inhibition cell death tumor microenvironment combination therapy
Mynediad Ar-lein:	http://www.sciencedirect.com/science/article/pii/S2666379125003866
Tagiau:	Ychwanegu Tag Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!